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ABSTRACT
Objectives: Enterotoxigenic Escherichia coli (ETEC) is one of the most common agents of diarrhea among other bacterial 
agents. Designing and producing vaccine against these bacteria is one of the major purposes of World Health Organization 
(WHO). Due to presence of diverse clones of ETEC strains in the world, the use of global vaccines for ETEC infection is 
controversial. B subunit of heat labile toxin (LTB) was introduced as a vaccine candidate molecule by several investigators. 
The expression of LTB gene isolated from a local bacterial strain and investigation of its immunological property was the 
objective of this study. 
Materials and Methods: LTB gene was isolated from a local isolated ETEC, cloned and expressed using pET28a expression 
vector. For LTB gene expression, the three main expression parameters (IPTG concentration, time and temperature of 
induction) were investigated. The recombinant protein was purified ( > 95%) with Ni-NTA column using 6XHis-tag and 
used as an antigen in ELISA test. 
Results: The immunological analyses showed production of high titer of specific antibody in immunized mice. Anti LTB 
Antibody could bind to whole toxin and neutralize the toxin through inhibition of its binding to the Ganglioside M1 receptor.
Conclusion:  The  recombinant  LTB  protein  is  a  highly  immunogenic  molecule.  Considering  the  LTB  role  in  ETEC 
pathogenesis, it can be taken into account as one of the most important components of vaccines against local ETEC.
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INTRODUCTION
Annually,  about  3  million  people  die  due  to 
gastroenteritis disease in the world. Viruses are the 
most common causes of gastroenteritis in developed 
countries, while bacterial agents are more common 
in  developing  countries  (1-3).  Enterotoxigenic 
Escherichia  coli  (ETEC)  is  the  most  important 
bacterial agent of diarrhea. Annually, ETEC strains 
cause 280-400 millions infected cases in children 
under 5 years old in developing countries  and impose 
400-800 thousands death per year (4). In addition to 
children and adults living in developing countries, 
disease is common among the peoples who travel 
to  endemic:  travelers  disease  (5,  6).  The  ETEC 121 ANTIBODy AgAINST ReCOMBINANT LTB
infection is also frequent after natural disasters such 
as earthquakes and flooding (7).
A vaccine to control ETEC infection could have 
a  significant  impact  on  morbidity  and  mortality 
caused by this bacterium. There are some evidences 
that  protective  immunity  may  be  effective  against 
this disease. Adults in developing countries are less 
frequently  affected  by  disease  and  some  travelers 
to endemic area are not influenced by disease even 
in  case  of  having  long  term  habitation. Therefore, 
designing  and  producing  vaccine  against  ETEC 
disease is amongst the important aims of hygienic 
organizations  such  as  world  health  organization 
(WHO) (8, 9).
Vaccine  candidate  molecule(s)  have  to  be  safe 
and  immunogenic  and  induce  protective  immunity 
against broad spectrum of ETEC strains.  Owing to 
this fact, heat labile enterotoxin (LT) B subunit is 
considered as a vaccine candidate molecule because: 
a) it is nontoxic subunit of LT molecule that play an 
important role in ETEC virulence and pathogenesis, 
b) most clinical ETEC isolate can produce LT and 
c) LTB is a potent immunogen and possess adjuvant 
properties (10-11).
Heat  labile  enterotoxin  consists  of  two  different 
subunits; heavy (LTA) and light chain (LTB). LTA 
is the toxic component because of its ADP-ribosyl 
transferase activity that induces diarrhea via activation 
of  adenylate  cyclase  which  increases  cyclic  AMP 
in the intestinal cells and causes the dehydratation. 
LTB is a 55 KD, homopentamer of 11.6 KD peptides 
which  join  non-covalently  to A  subunit  and  binds 
to  ganglioside  GM1  receptors  on  the  surface  of 
enterocytes (12). 
LTB has much similarity to cholera toxin B subunit 
(CTXB) structurally, functionally and genetically (11). 
Cholera vaccine (Dukoral©) which has license of use 
in 15 different countries, also contains recombinant 
cholera toxin B subunit (CTXB). The most important 
disadvantage  of  this  vaccine  is  its  short  period  of 
protection (3-6 month) (8, 9). The effectiveness of 
global vaccine against ETEC is challenged by several 
studies due to diverse clones of ETEC strains in the 
world depending on factors such as natural climates, 
nutrition and hygienic culture. So, specific vaccine 
was suggested for different geographical regions of 
the world (13).
In this study we describe isolation and expression 
of  LTB  gene  from  a  local  isolate  of  ETEC.  The 
purification of recombinant LTB, its immunogenicity 
and  effectiveness  of  antibody  against  rLTB  in 
inhibition  of  LT  binding  to  its  receptor  (GM1)  is 
investigated as well.
MATeRIALS AND  MeTHODS
Bacterial strain and genomic DNA extraction. 
An ETEC bacterium isolate (Reference laboratory of 
Bu Ali hospital, Tehran, Iran) was cultivated in LB 
broth.  Bacterial  genome  was  extracted  by  CTAB-
NaCl  method  and  its  concentration  was  measured 
by  spectrophotometer  (OD  260  and  280nm). 
Electrophoresis on 1% agarose gel was also done to 
determine the quality of isolated DNA (14). 
Primer  design  and  PCR.  Primer  pair  was 
designed  based  on  deposited  data  in  gene  bank 
(Accession  No  M17874)  for  conserved  domain 
of  B  subunit  of  heat  labile  toxin  (LTB).  Forward                                                                                                               
(5’TGTGCAGAATTCGCTCCTCAGTC) and reverse     
(5’TTACAAGCTTCTAGTTTCCATACTGATTG) 
primers containing EcoRI and HindIII sites (under 
lined) respectively for subsequent cloning procedure.
The  LTB  gene  (312bp)  was  amplified  using  pfu 
DNA polymerase (Fermentas, Lithuania) in a  reaction 
mixture (25 µl) containing DNA (50 ng) in the presence of   
2.5 mM magnesium sulfate, 0.4 mM  of each nucleotide 
and 0.8 pM of each primer. Cycling conditions contain 
initial denaturation ( 94°C, 5 min) followed by  30 
cycles of 94°C for 30 sec, 58°C for 30 sec, 72°C for 
60 sec and final extension at 72°C for 10 min. PCR 
products  were  analyzed  by  electrophoresis  on  1% 
agarose gels and ethidium bromide staining.
PCR product analysis and cloning. The authenticity 
of PCR product was determined by restriction enzyme 
digestion and sequencing. The LTB gene was digested 
with EcoRI/HindIII restriction enzyme and cloned in 
the same site in pET28a expression vector (Novagen, 
Canada) under the control of chemically inducible T7 
promoter. The accuracy of cloning was determined 
by PCR with specific primers and restriction enzyme 
digestion.
Optimization of rLTB expression in E. coli host. 
Recombinant pET28a-LTB plasmid was transformed 
into  competent  E.  coli  strain  BL21DE3plysS 
(Stratagen, USA) by standard procedure. The rLTB 
expression was optimized for inducer (isopropyl-b-
D-thiogalactopyranoside, IPTG) concentration (0.25, 122 SALMANIAN  eT AL .                                                                                             IRAN. J. MICROBIOL. 2 (3) : 120-127 
0.5, 0.75, 1 and 1.5 mM), incubation times (1, 2, 3, 
4 and 5 hours) and incubation temperatures (25, 35 
and 37°C). 
  Analysis  of  rLTB  by  SDS-PAge.  Protein 
expression in induced E. coli cell was analyzed on 
12% denaturized polyacrylamide gel electrophoresis. 
Briefly, 5 ml of the induced cells were centrifuged 
(5000 g, 10 min) and sonicated on ice (45s, in 75% 
maximum  outputs). The  protein  concentration  was 
determined by Bradford assay (15).  Equal amounts 
of  each  sample  were  analyzed  by  SDS-PAGE.  To 
determine  the  form  of  expressed  protein  (soluble 
vs. inclusion body), bacterial cells were centrifuged 
(5000 g, 10 min) and one part was resuspended in 
buffer A (PBS pH 7.2) and sonicated as above. Another 
part was resuspended in buffer B (PBS containing 8M 
urea) followed by incubation at room temperature for 
45 min and centrifuged (5000 g, 10 min). Supernatant 
of two parts were collected after centrifugation and 
analyzed on SDS-PAGE (12%) (16).
rLTB purification by Ni-NTA affinity chromato- 
graphy  column.  For  purification  of  the  rLTB, 
the  recombinant  E.  coli  cells  were  grown  under 
optimized  condition  and  resuspended  in  B  buffer 
(above) and sonicated. The supernatant was separated 
by  centrifugation  (5000  g,  4º  C,  and  10  min)  and 
loaded  on  Ni-NTA  column  (Qiagen,  Canada). The 
purification was performed according to the protocol 
provided by manufacturer. LTB fraction was dialyzed 
overnight against PBS pH 7.2 and stored at -70°C 
until use.
Immunoblot  analysis.  As  described  previously, 
LTB  is  structurally  very  similar  to  B  subunit  of 
cholera toxin (CTXB). Therefore the rabbit antisera 
against CTXB (Sigma) produced in our laboratory 
by  immunization  of  rabbit  with  CTXB  was  used 
for detection of LTB protein. Briefly, the separated 
recombinant protein bands through 12% SDS-PAGE 
were transferred to nitrocellulose membrane (Roche, 
Germany)  using  a  Mini Trans  Blot  electrophoretic 
transfer cell (Bio-Rad, USA). The transfer process 
carried out using 300 mA current for 1 h in the transfer 
buffer (50 mM Tris, 40 mM glycine, 0.04% SDS, 20% 
methanol, pH 8.3). Non-specific antibody reactions 
were blocked by incubation of membranes in 10 ml 
of 5% skim milk in PBST buffer (PBS, 0.05% Tween- 
20,  pH  7.2)  at  room  temperature  for  two  hours. 
The membrane was then incubated for 1 h at room 
temperature in 10 ml of 1: 200 dilution of rabbit anti-
CTXB antiserum. The membrane was washed four 
times in PBST buffer followed by incubation for 1 h 
at room temperature in 1: 2000 dilutions of anti-rabbit 
IgG conjugated with horseradish peroxidase (Dako, 
Denmark). After washing, color was developed with 
3, 3′-Diaminobenzidine (DAB) (Sigma, Germany) in 
buffer (10 mM Tris, pH 7.5, 10 µl H2O2). 
Heat labile toxin production and purification. 
For GM1 inhibition assay, it was necessary to use 
heat labile toxin (LT) as a positive control. Therefore, 
the LT was purified from an enterotoxigenic E.coli 
strain as described by Kunkel and Robertson, 1979 
and Menezes et al., 2006 (17, 18). Briefly, the LTB 
producing strains were cultivated in media containing 
2%  casamino  acids,  0.15%  yeast  extract  and  1% 
glucose at 37ºC, 200 rpm for 18h. The well grown 
bacterial  culture  was  incubated  with  polymyxin  B 
(1mg/ml, final concentration) for further 30 minutes 
and centrifuged (1600 x g /20 min). Solid ammonium 
sulphate  was  added  to  the  supernatants  to  90% 
saturation with stirring at 4 ºC and kept overnight. 
After centrifugation, the pellet was resolved in Tris 
buffer (0.02 M pH 8) and dialyzed against the same 
buffer at 4 ºC overnight. 
gM1-ganglioside  binding  assay  for  LT.  The 
binding  of  LT  to  GM1-ganglioside  receptor  was 
determined  by  GM1-ELISA  as  described  by 
Svenerholm and Wiklund, 1983 and Ma et al., 2006 
Fig. 1. Analysis of PCR product on 1% agarose gel. 
Genomic  DNA  was  extracted  from  ETEC  and  the 
LTB gene was amplified using the specific primers. 
Lane 1:  PCR product of LTB gene (312 bp). M: 100 
bp DNA ladder.
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(19,  20).  ELISA plates (NUNC, Denmark) were coated 
with 100μl (3.0 μg) per well of monosialoganglioside 
GM1  (Sigma,  G-7641),  dissolved  in  bicarbonate 
buffer and incubated at 37°C (2 h). BSA was used as 
negative control. The wells were washed (four times) 
with PBST and blocked by skim milk solution 2% 
(w/v) in PBST. The wells were loaded with serially 
diluted LT (100 μl per well) and then covered with 
1:500 dilution of rabbit anti-CTXB primary antibody 
(100 µl). The wells were then incubated with 1:5000 
dilution  of  goat  anti-rabbit  IgG  conjugated  with 
horseradish  peroxidase  (Sigma)  in  PBST.  Each 
step  completed  with  1h  incubation  at  37ºC  and  4 
times washing with PBST. Finally plates developed 
with 100 µL per well of OPD (Sigma) substrates in 
citrate-phosphate buffer (pH 5) for 20 min at room 
temperature in dark. After stopping the reaction with 
sulfuric acid (2.5 M), the plate was read at 492 nm 
with an ELISA reader (Dynex, USA).
Humoral immune responses after immunization 
with rLTB. Affinity purified recombinant LTB protein 
(20 µg) was injected subcutaneously (S.C.) along with 
complete Ferund’s adjuvant. Up to 3 booster doses 
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Fig. 2a.  Analysis of the recombinant LTB expression after 
IPTG induction by SDS–PAGE. The different clones were 
analyzed after IPTG induction for the expression of LTB 
by SDS-PAGE. Lane 1, 3, 5:  The induced bacteria. Lane 
2, 4, 6:  The same bacteria before induction. M: protein 
Molecular weight marker.
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Fig.  2b.  Analyses  of  expressed  LTB:  soluble  protein  vs. 
inclusion body. After induction, the cells were sonicated in 
the presence or absence of 8M urea and analyzed by SDS-
PAGE. Lane 1: The cells extract in non denaturing condition 
(PBS  buffer).  Lane  2,  3:  The  cells  extract  in  denaturing 
condition (PBS containing 8 M urea). M: protein molecular 
weight marker.
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Fig.  2c.  Purification  of  rLTB  by  Ni-NTA  column.  Lane 
1:  Protein  sample  before  purification.  Lane  2-4:  Protein 
sample  in  washing  buffer  fractions  before  elution.  Lane 
5: Purified rLTB in elution buffer. M: Protein molecular 
weight marker.
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Fig.  2d.  Immunoblot  analyses  of    recombinant  LTB  by 
specific antibody. Lane 1: Protein molecular weight marker. 
Lane 2: Immunoblotting with anti-CTXB antibody to detect 
rLTB protein. Lane 3: Negative control (bacterial lysate 
without IPTG induction).124 SALMANIAN  eT AL .                                                                                             IRAN. J. MICROBIOL. 2 (3) : 120-127 
were  also  injected  S.C.  with  incomplete  Ferund’s 
adjuvant with 2 weeks intervals. Bleeding was done 
two weeks after final booster and mouse serum were 
collected. Anti-LTB  IgG  purified  by  protein  G  on 
Sepharose 4B fast flow column (Sigma).  
Indirect ELISA was used for antibody titration. A 
96-well ELISA plates (NUNC, Denmark) were coated 
with LTB protein (10 µg/ml) in carbonate-bicarbonate 
buffer  by  2h  incubation  at  37°C.  The  plates  were 
washed  with  PBST  (4X),  blocked  with  skim  milk 
solution  2%  (w/v)  in  PBST  and  then  incubated 
with a serial dilution (1: 2000 to 1/64000) of mouse 
anti-LTB antiserums in PBST for 1 h at 37°C. The 
remaining steps were performed as described above 
with  the  exception  of  using  HRP  conjugated  anti-
mouse antibody (Sigma) as secondary antibody. The 
sera collected from mice before immunization was 
used as negative control. 
Toxin neutralization assay. To study the efficiency 
of sera from immunized mice to block the binding of 
LT to its receptor (GM1), a GM1 binding inhibition 
assay  was  carried  out.  Serially  diluted  sera  from 
immunized mice were incubated (37°C, 1 h) with LT 
(2 µg/ 100 µl). The mixture of sera and LT was then 
added to the GM1 pre-coated wells and the GM1-
ELISA was performed as described previously (21).
ReSULTS
LTB gene amplification and cloning.  The LTB 
gene  from  ETEC  bacteria  was  amplified  by  PCR 
(Fig. 1). The PCR product was further analyzed by 
restriction enzyme digestion and sequencing in both 
direction  (data  not  shown). The  PCR  product  was 
digested  with  HindIII  and  EcoRI  and  cloned  into 
pET-28a which was digested with the same restriction 
Fig. 3. Titration of anti-rLTB antisera. Titers of IgG against 
rLTB were determined by ELISA in the sera of immunized 
mice. The sera were serially diluted (1: 2000 to 1: 64000) 
and  used  in  ELISA  test.  The  data  presented  as  three 
independent measurements. 
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Fig. 4. Heat Labial-toxin neutralization assay. The inhibition of the binding of LT to GM1 receptor was determined using 
GM1 ELISA assay. 4a: Serially diluted LT (2000-125 ng) in PBS was added to GM1 coated ELISA plates. 4b: as figure 
shows the serially diluted sera from immunized mice could block the binding of LT to GM1 receptor. Each graph shows the 
mean OD ± SD in three independent experiments.
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enzymes.  Recombinant  pET28a-LTB  were  further 
analyzed  by  sequencing  and  restriction  enzyme 
analysis (data not shown). 
rLTB expression and purification. The recombinant 
E. coli bacteria were induced in optimized condition 
(1 mM IPTG after 3h at 37ºC). The SDS-PAG analysis 
show successful expression of rLTB protein (Fig. 2a). 
The majority of recombinant LTB was accumulated 
in the form of inclusion bodies (Fig. 2b). Following 
Ni-NTA affinity chromatography and several washing 
steps,  the  rLTB  was  purified  from  the  column  by 
elution buffer (Fig. 2c). For confirmation of purified 
rLTB,  it  was  electrotranfered  to  nitrocellulose 
membrane  and  identified  by  immunoblotting.  The 
reaction with anti CTXB antiserum (Fig. 2d) stained 
a protein band around 15.5 KD and reconfirmed the 
purification of rLTB. 
Immune  sera  antibody  titration.  The  humoral 
immune responses of immunized mice were measured 
by ELISA technique. The data showed that high titer 
of anti-rLTB antibody was produced by immunized 
mice. As shown in Fig. 3, after one injection and 3 
boosters, all mice were hyper immunized and anti-
rLTB antibody titer received up to 1/64000.
Analysis  of  neutralizing  antibody.  To  examine 
the  biological  activity  of  rLTB-specific  antibodies, 
their  efficiency  to  neutralize  the  heat-labile  toxin 
was  investigated  by  a  GM1-binding  inhibition 
assay.  The  GM1-ganglioside  binding  assay  of  LT 
demonstrated  the  specific  binding  of  purified  LT 
to GM1. The titration curve shows that purified LT 
binds to GM1 receptor from 2 μg to 125 ng (Fig. 4a). 
For analysis of neutralizing antibody, serum samples 
from  immunized  mice  were  subjected  to  GM1-
ELISA.  Serum  antibodies  from  control  mice  were 
used as negative controls. Binding of LT to the coated 
GM1 ganglioside was blocked (up to 80%) by serum 
samples  isolated  from  immunized  mice.  The  sera 
from control mice or PBS have shown no reaction 
(Fig. 4b).
DISCUSSION
 It has been estimated that 30-70% of gastroenteritis 
is  caused  by  bacteria.  Among  bacterial  agents, 
enterotoxigenic E. coli (ETEC) is the most common 
agent.  Nowadays,  ETEC  morbidity  and  mortality 
rate has been increasing due to emergence of ETEC 
antibiotic  resistance  and  inefficient  treatment. 
Developing  countries  including  Iran  with  tropical 
weather are among the regions that encounter sanitary 
issues such as ETEC diarrhea especially in children 
under 5 years age (1- 3). Taking these issues in to 
consideration, trying to preclude ETEC infection is 
one of the main sanitary purposes.
Literature review indicates the attempts of several 
groups on ETEC vaccine development to control the 
disease (8, 9). One of the major points that should 
be considered in vaccine development is induction 
of  long  term  (at  least  2  years)  protection  in  most 
immunized individuals. Moreover vaccine candidate 
molecule/s has to be selected from the conserved set 
of pathogenic important molecules, so that most ETEC 
strains posses them (8, 9). The effectiveness of global 
vaccine against ETEC is challenged by several studies 
due to the presence of diverse clones of ETEC strains 
in different parts of the world. So, specific vaccine 
was  suggested  for  different  geographical  regions 
(13).  Regarding  all  findings,  this  study  was  done 
using a regional strain of ETEC and LTB molecule 
as  binding  domain  of  heat  labile  toxin,  which  is 
reported that most of ETEC clinical isolate posses it. 
It was reported that the presence of antibody against 
LTB can block the binding of the toxin to epithelial 
cells and decrease the related effects of toxin release 
(water  and  electrolyte  loss)  (22,  23).  Yamamoto 
and coworker was cloned the LTB and reported its 
necessity for developing vaccine against ETEC (24). 
Immunomodulatory effect was also reported for the 
LTB (25). Based on this property, it shows adjuvant 
effect and up-regulates the immune response against 
the vaccine components (26).
In  this  study,  the  gene  encoding  for  LTB  was 
isolated from local isolate of enterotoxigenic E. coli 
that causes diarrhea in humans. A DNA fragment of 
the expected size ( near 300 bp) was amplified by 
PCR and expressed using chemically inducible T7 
promoter (pET28a). 
The  best  condition  for  the  recombinant  rLTB 
expression  was  achieved  by  changing  the  IPTG 
concentration,  bacterial  culture  temperature  and 
duration of induction. The expression yield increased 
with  ascending  concentration  of  IPTG  from  0.25 
to  1  mM,  while  increasing  inducer  concentration 
to 1.5 mM showed no effect on protein expression. 
Therefore it can be postulated that in this situation 
the T7 promoters were saturated in 1 mM IPTG. The 126 SALMANIAN  eT AL .                                                                                             IRAN. J. MICROBIOL. 2 (3) : 120-127 
require time after induction was another factor that 
has been investigated. Protein expression increased 
with bacterial culture duration up to 3 hours. But after 
4 and 5 hours, expressed protein decreased slightly. It 
seems that in long term induction, following high level 
expression of rLTB, some of the cells don’t tolerate 
this condition and lysed. In this case, the recombinant 
protein from lysed cells releases into culture media 
and degraded. In order to inhibit protein accumulation 
in inclusion body and increasing its solubility, culture 
incubation  was  performed  at  room  temperature 
(25°C). In this temperature bacterial cell metabolism 
and protein synthesis decrease but, rLTB showed the 
tendency to aggregate, yet. However, high expression 
of rLTB was an advantage but its accumulation in the 
form of inclusion bodies makes limited complication 
in protein extraction process. De Mattos Areas AP, 
was reported the same problem for CTB expression 
(27). Rezaee et al.  used Saccharomyces cerevisiae for 
expression of LTB and reported that it could be an 
effective strategy to protect the animal model against 
ETEC infection (28).
The  rLTB  was  separated  on  SDS–PAGE  and  its 
biochemical nature was confirmed by immunoblotting 
using  anti-CTXB  antiserum.  Based  on  6XHis-tag 
and using Ni-NTA column, the recombinant protein 
became highly purified (> 95%). The purified rLTB 
was used for immunization of mice. The ELISA test 
results showed that all immunized mice produced high 
titer of anti LTB antibody after four times injection 
with rLTB. This result can be related to LTB function 
as immunostimulator and its adjuvant property (26). 
GM1 ganglioside binding assay is widely used for 
detection of LT and cholera toxin (19- 21). This study 
show  that  antibody  against  rLTB  could  neutralize 
the toxin and efficiently inhibited it’s binding to the 
corresponding receptor (GM1). This data demonstrate 
that antibody against recombinant LTB can recognize 
native  form  of  LTB  in  holotoxin  and  possess  the 
ability to block the LT binding to its receptors. 
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